bluebird bio opens gene and cell therapy manufacturing facility

bluebird bio has opened its state-of-the-art gene and cell therapy manufacturing facility in Durham, North Carolina.

The facility will produce lentiviral vector for the company’s investigational gene and cell therapies – including bb2121 and bb21217 – for the treatment of multiple myeloma and potentially LentiGlobin for the treatment of transfusion-dependent β-thalassemia (TDT) and sickle cell disease.

bluebird bio purchased the facility in November 2017. Once completed, the company will have invested more than $80 million building a world class site equipped with multiple manufacturing suites capable of producing lentiviral vector (LVV).

The facility also includes warehouse and quality control testing laboratories. Construction is substantially complete and equipment qualification is underway.

Initially, bluebird bio expects the facility to produce clinical and commercial supply of lentiviral vector, which is a critical component of the company’s gene and cell therapies.

The facility is large enough to accommodate significant future expansion, including the possibility of manufacturing commercial drug product.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...

New class of precision medicine strips cancer of its DNA defences

A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class. The...

Tonix & Southern Research expand COVID-19 vaccine collaboration to include T cell study

New York biopharma, Tonix Pharmaceuticals, has expanded its strategic collaboration with Southern Research to include a study of T cell immune responses to SARS-CoV-2...

Related news

CPhI South East Asia confirms new November date

CPhI South East Asia has postponed its rescheduled event to November 4-6, 2020 to provide more time for positive business conditions to return and...

Execs call for track-and-trace schemes in Southeast Asia – report

Thailand and Indonesia have the largest near-term generics export potential as regional executives come out in favour of an ASEAN-wide track and trace scheme. So...

Winners of CPhI Pharma Awards revealed

The winners of the 2019 CPhI Pharma Awards, which aims to celebrate the industry’s top innovators, performers and outstanding achievements, have been announced. The ‘CEO...

Finalists revealed for CPhI Pharma Awards

The finalists for the CPhI Pharma Awards at the forthcoming CPhI Worldwide event have been announced. The shortlist spans thirteen different award categories covering the...